Evaluating a new antibody therapy to prevent Alzheimer’s disease

Lead Investigators: Dr Mark Good & Dr Emma Kidd
Institution: Cardiff University
Grant type: PhD
Duration: 3 years
Amount: £74,897

 

Scientific Title: An evaluation of steric hindrance of APP processing by 2B12 as a treatment for amyloid-related pathology in a murine preclinical model of Alzheimer's disease.

What do we already know?

One of the hallmarks of Alzheimer's Disease is accumulation of the amyloid-beta protein which forms toxic plaques in the brain.

 

Amyloid-beta is a by-product from the degradation of a larger protein, Amyloid Precursor Protein (APP).

 

Could APP be targeted to prevent plaque formation?

What does this project involve?

Dr Good has developed antibody 2B12 which prevents APP degradation, and therefore the production of amyloid-beta.

 

The PhD student is continuing this work, testing the effect of the 2B12 antibody on memory and amyloid-beta production in a mouse model of Alzheimer's disease.

How will this benefit people with dementia?

If successful, this study could lead to the development of the 2B12 antibody, and similar methods of preventing amyloid plaque formation, as preventative treatments of Alzheimer's disease.

 

Back to list of current projects